Australasian Leukaemia & Lymphoma Group in Fitzroy, Victoria | Medical research centre

Australasian Leukaemia & Lymphoma Group

Locality: Fitzroy, Victoria

Address: Ground Floor, 35 Elizabeth Street 3121 Fitzroy, VIC, Australia

Website: https://www.allg.org.au/support-us/make-a-donation/

Likes: 853

Add/Update information

Reviews

Tags

• Non-profit organisation
• Charitable organisation
• Community organisation
• Medical research centre

25.01.2022 The @ALLGtrials National Blood Cancer Registry (NBCR) has now surpassed 2,000 participants! This milestone cements the NBCRs position as ANZs largest collection of real-world data on acute myeloid leukaemia (AML) as well as a major source of data on acute lymphoblastic leukaemia (ALL) and several uncommon lymphomas. NBCR Ambassador and ALLG Scientific Advisory Committee member, A/Prof Andrew Wei from the Alfred Hospital commented, From the inception of the NBCR in 2012, we... have now surpassed the milestone of 2000 participants, which is a wonderful achievement for the ALLG, its members and the many generous stakeholders who have supported our vision. The NBCR functions as a vital gateway to ALLG clinical trials and represents the single largest repository of data for Australian patients with acute leukemia and other blood cancers. The NBCR will make a vital contribution to knowledge and future advancements in the field of blood cancers. Read more about the ALLGs commitment to delivering the NBCR and NBCR-related clinical trials on https://www.allg.org.au/nbcr_surpasses_2000

24.01.2022 The ALLG has launched a new clinical trial this week to help improve treatment for people with newly diagnosed mantle cell lymphoma (MCL), a type of non-Hodgkin lymphoma. The ALLG NHL33 trial is looking at the impact of adding acalabrutinib oral capsules in the induction and maintenance phases of standard treatments on stopping or slowing the growth of cancer cells. The Australia-wide trial is led by Chief Investigator Associate Professor Eliza Hawkes from the Austin Hospita...l in Melbourne and has begun patient recruitment the Austin as well as Gosford and Wyong Hospitals in NSW. Between 15 and 20 sites across Australia will open with the aim of recruiting 44 patients over three years. Importantly, the trial will incorporate a tele-trials model with two remote sites under the lead tele-trials site of Townsville Hospital. The team at the Austin Hospital, including A/Prof Hawkes and lead research fellow Dr Allison Barraclough, are excited to begin this study to help MCL patients. A/Prof Hawkes said, Im pleased to be contributing to the global efforts to improve outcomes in this rare disease and Im really excited to be working with my colleagues at rural and remote centres on this novel Telehealth model so we can reach Australian Haematology patients who usually face travelling impossible distances to participate in a clinical trial. The ALLG thanks AstraZeneca and Sandoz for their support of ALLG NHL33. Read the full article on: https://www.allg.org.au/allg-launches-new-trial-for-mantle/

24.01.2022 This year, 17,000 Australians were diagnosed with a blood cancer. People just like Linda, 66, from Hobart. Linda was diagnosed with Follicular Lymphoma and her doctor recommended she join a new international clinical trial, NHL30 PETReA. The ALLG is facilitating access to this trial for Australian patients. Linda said, I was lucky enough to be given the opportunity to take part in the NHL30 trialwhich also gave me the benefit of extra monitoring for my cancer.... My follicular lymphoma has now gone into complete remission, which is just amazing! I’m so grateful that I could access this international trial through the ALLG in Australia. The ALLG has helped over 10,700 patients access the best global treatments through our clinical trials. With your help, we can provide access to so many more Australians living with blood cancer just like Linda. Please make a Christmas gift to support ALLG’s blood cancer research today at www.allg.org.au/support-us/make-a-donation

24.01.2022 And that's a Wrap!! What a fantastic and successful week it's been of science and education for our members at the October Virtual Scientific Meeting 2020! Thank you to all our members for their involvement as speakers and attendees. Thank you as always to our Diamond, Gold and Silver sponsors for their wonderful and continued support of our Scientific Meeting. See you all at the next one in Melbourne (or virtual) 10-14th May 2021!

23.01.2022 The ALLG together with the HSANZ welcomed the opportunity to provide a submission and contribute to the inquiry into the approval process for new drugs and novel medical technologies in Australia. To view submission #112 click here: https://www.aph.gov.au//Health_Aged_C/Newdrugs/Submissions. Our key messages were solutions to accelerate research and increase clinical trials for patients #healthgovau #australiangovernment

23.01.2022 Living with blood cancer can be really tough for patients, carers and families at the best of times. This year has been especially difficult for so many reasons -- facing COVID-19, isolation from family and friends, and with disruption and uncertainty all around. Its easy for our mental health to take a backseat. Today is R U OK? Day. Theres never been a better time to check in with your loved ones and ask them this important question. You dont have to be an expert to ask ...this important question and support your family and friends. You just have to ask! Check out this great video from R U OK Day? for some tips on how to keep the conversation going and support your family and friends. https://ruok.vudoo.io/watch/16561128133

23.01.2022 Check out the latest ALLG News issue, featuring articles on: **** A/Prof Peter Mollee's recent Journal of Clinical Oncology publication on improving treatments for AL amyloidosis (ALLG MM13). **** The latest on ALLG clinical trials to help patients with acute myeloid leukaemia (ALLG AMLM23 and AMLM25), chronic myeloid leukaemia (ALLG CML13), mantle cell lymphoma (ALLG NHL33) and those who have undergone bone marrow transplantation (ALLG BM12).... **** Upcoming ALLG and haematology events and webinars, including the ALLG October Virtual Meeting and the American Society of Hematology. **** The ALLG team who works hard to accelerate blood cancer trials across Australia and New Zealand. Read the ALLG News here: https://www.allg.org.au///allg-news-aug-2020-final_web.pdf

22.01.2022 @ALLGtrials Member A/Prof John Moore has had a big few weeks! Not only did @DeltaGoodrem announce with A/Prof Moore the launch of the @DGFoundation Fellowship in partnership with @SVHSydney, which will support cell therapy research, but also he has become the latest to open the ALLG BM12 clinical trial focused on helping patients who have undergone bone marrow transplantation for acute leukaemia or myelodysplasia. The trial is looking specifically at whether a medication cal...led cyclosphosphamide is better than the current standard medications at preventing graft versus host disease (GVHD), which is a complication of bone marrow transplantation. Read more about the Delta Goodrem Foundation here: https://www.supportstvincents.com.au//delta-goodrem-found/ Read more about ALLG clinical trials here: https://www.allg.org.au/clinical-t/current-clinical-trials/

20.01.2022 Today is National Bandanna Day and in support of Canteen Australia @ALLGtrials is supporting the #BandannaDay campaign. Funds raised for this very worthy cause will help young people impacted by cancer get access to programs, counselling and peer support

20.01.2022 Attention healthcare professionals involved in treating blood cancer! The University of Melbourne, in collaboration with the Leukaemia Foundation, are surveying both blood cancer patients and health professionals about their experiences during the COVID-19 pandemic. The survey is aimed at better understanding the unique experiences and perspectives of health professionals involved in the care of haematology patients during the COVID-19 pandemic. This is to help us develop s...ervices that better meet the changing needs of health professionals during these exceptionally difficult times. If you are a clinician, nurse, or allied health professional (e.g. social worker, psychologist, exercise physiologist, dietitian, occupational therapist, physiotherapist), you are invited to participate in a short survey (15 minutes to complete) exploring how COVID-19 has impacted you as a healthcare professional and the care you provide to haematology patients. The research team is interested in understanding the challenges you may have faced and the ways that healthcare professionals have used their skills and resources to adapt service delivery. This study is being conducted by: Dr Nienke Zomerdijk (responsible researcher), Dr Camille Short, Dr Michelle Jongenelis, Prof Jane Turner, Dr Eva Yuen, Mr Andrew Smith, Ms Maryanne Skarparis, Mr Greg Zotos and Ms Kathryn Huntley. To participate or find out more, visit: https://melbourneuni.au1.qualtrics.com//form/SV_beCloJjOmP The survey closes at the end of September.

19.01.2022 Happy New Year! There’s no better way to kick off 2021 than by saying a huge Thank You to all of our amazing donors, fundraisers and supporters. We’re so grateful for your support for the ALLG. With you, we simply wouldn’t be able to continue our critical research into blood cancer. Every dollar that you donate or fundraise helps the ALLG achieve our mission of better treatments and better lives for blood cancer sufferers. With your help, we can cure blood cancer once and ...for all. For more info on the ALLG, please visit www.allg.org.au

19.01.2022 After an amazing turnout on Monday, our first day of the first-ever Australasian Leukaemia & Lymphoma Group - ALLG Virtual Scientific Meeting, we've continued to gather a great collaborative audience of ALLG Members and Sponsors delegates from across Australia and New Zealand for Days 2 and 3. Today (DAY 3) we have an exciting program of the Transplantation & Cell Therapies Working Party session led by Dr Nada Hamad and the ALLG Associate Member Operations Meeting led by the ALLG Project Management team. #ALLGtrials #clinicaltrials #virtualconferences

19.01.2022 What a great day it was collaborating with the HSANZ on a very successful Baikie Symposium and Pitney Fellow address. Chaired by HSANZ President Leanne Berkahn and Vice President Steven Lane Congratulations to Danielle Oh on winning the 2020 Baikie Symposium Award for best research!!

18.01.2022 SAVE-THE-DATE FOR ALLG MEMBERS & PARTNERS! The ALLG October Scientific Meeting is going fully virtual the week of October 12, 2020. We are working with the ALLG Scientific Advisory Committee (SAC), Working Party Chairs and Membership Relations Working Group (MRWG) to deliver an exciting and engaging scientific program for Members. Stay tuned as more details on the meeting will be provided soon.

18.01.2022 Thank you for your support for the ALLG in 2020. This year, we’ve opened 5 new trials and provided over 300 blood cancer patients access to the best new global treatments via our clinical trials. We have three more international clinical trials for Australian patients ready to open right now but we need your help. Each trial costs ALLG between $700,000 and $2 million dollars to run. The ALLG doesn’t receive any ongoing funding and relies on people just like you to help our ...members continue their critical medical research into blood cancers. Your donation this Christmas will help ALLG bring the world’s most promising blood cancer research and treatments to Australian patients. With your help, we will cure blood cancer once and for all. www.allg.org.au/support-us/make-a-donation

16.01.2022 Today is World Lymphoma Day, and in support of our friends at Lymphoma Australia, we are supporting the #LoveBombLymphoma campaign...going Lime for Lymphoma and sending love bombs to all our members and supporters affected by lymphoma.

16.01.2022 Meet Nathalie, who has volunteered as an ALLG Consumer Representative since 2016. Nathalie lives with a myeloproliferative neoplasm (MPN) called polycythaemia vera. On the eve of the 8th annual #MPNAwarenessDay, we thank Nathalie for her dedication to raising awareness for MPN, other blood disorders and clinical trials to support #BetterTreatmentsBetterLives. Her commitment to helping others is greatly appreciated! Check out the #MPNAwarenessDay events hosted by our friends... at the Leukaemia Foundation of Australia and MPN Alliance Australia. https://www.leukaemia.org.au/events/mpn-awareness-day-webina

16.01.2022 NAIDOC Week: Celebrating history, culture & achievements of Aboriginal & Torres Strait Islander peoples. This year’s theme for NAIDOC Week ‘Always Was, Always Will Be’ recognises that First Nations people have occupied & cared for this continent for over 65,000 years. #NAIDOCWeek #NAIDOCWeek

16.01.2022 The Australasian Leukaemia & Lymphoma Group - ALLG proudly supported its friends at Lymphoma Australia during their recent Virtual Patient and Carer Education Day. The ALLG's own Kate Halford presented on the day, introducing the ALLG and describing the clinical trials that the ALLG sponsors for people living with #lymphoma. https://www.youtube.com/watch?v=_aPSrT5ZpSg

15.01.2022 The end of financial year is fast approaching but theres still time to make a tax-deductible donation to support critical blood cancer research! Your support over the last 12 months enabled Australasian Leukaemia & Lymphoma Group - ALLG to open 8 new trials and provide 480 blood cancer patients access to new treatments via clinical trials. But we need to do moreand we need your help.... Any donation, large or small, will make a real difference to Australian patients. All donations over $2 are tax-deductible. Please visit https://www.allg.org.au/support-us/make-a-donation today.

14.01.2022 Cancer doesnt stop. During COVID-19, the ALLG has been working tirelessly for blood cancer patients. We have continued our vital clinical trials and collaborated with clinicians and cancer foundations to develop critical patient support information. Blood cancer patients are some of the most at-risk people in the community during the COVID-19 pandemic. This makes continuing medical research into better treatments for blood cancer patients more critical than ever.... Please consider making a donation to ALLG this tax-time. Your donation will ensure that we can continue to deliver life-changing treatments to blood cancer patients through this difficult time. Please visit www.allg.org.au/support-us/make-a-donation today.

14.01.2022 Last month the ALLG farewelled Dr David Yeung from the Scientific Advisory Committee (SAC). We wish him all the very best and thank him for his significant and valued contribution. Dr Yeung has handed over to Dr Matthew Greenwood as the newest member of the SAC. Congratulations Dr Greenwood on your appointment and welcome!

13.01.2022 Congratulations to Clinical Oncology Society of Australia - COSA on their 47th Annual Scientific Meeting last week. The ALLG’s Operations Manager, Tracey Gerber presented on ‘The Effect of the COVID-19 Pandemic on Patient Recruitment to the ALLG Clinical Trial Portfolio' #COSA20

13.01.2022 The Australasian Leukaemia & Lymphoma Group - ALLG completed a successful #EHA25virtual congress. For the full wrap-up on ALLG-related activities at EHA, please see the latest issue of ALLG News on https://www.allg.org.au/allg-completes-successful-eha-virt/. Additionally, if you are a healthcare provider, you can catch the ALLG-supported "EHA Game-Changers" webcast tonight Thursday, July 2, 7-830pm AEST, through The Limbic network. Dr Tara Cochrane and A/Prof Anoop Enjeti are representing the ALLG as panelists, providing reviews of the key publications from #EHA25virtual. Register through TheLimbic.com/haematology.

13.01.2022 The American Society of Clinical Oncology (ASCO) and AML Hub have both featured ALLG leader A/Prof Andrew Wei from The Alfred Hospital in their online video programs. In the presentations, A/Prof Wei speaks about the VIALE-C trial results and recommendations for venetoclax-containing therapies for older adults with acute myeloid leukaemia (AML). These findings are important as the ALLG with A/Prof Wei are gearing up to launch the ALLG AMLM25 (INTERVENE) clinical trial, which... will be looking at the safety and effectiveness of adding two new therapies to the standard venetoclax-containing regimen for those aged >60 years with AML who have not already received previous chemotherapy or who are not able to receive intensive initial therapy. ASCO Post: https://ascopost.com//andrew-wei-on-venetoclax-plus-cytar/ JNCCN 360: https://jnccn360.org//safely-administering-a-venetoclax-c/ AML Hub: https://aml-hub.com//6-month-update-on-the-phase-iii-viale

12.01.2022 The week of the October Virtual Scientific Meeting has come & gone, but the good news is, you can still access the virtual platform for the next few months!! Simply sign back in & watch any of the pre-recorded sessions available on demand in the Theatre of the digital platform.

12.01.2022 Australasian Leukaemia & Lymphoma Group - ALLG Virtual Scientific Meeting has run out DAYS 4 & 5 with a bang! Record attendance at the ALLG Supportive Care Working Party session, the Special COVID-19 & Haematological Malignancy session as well as the ALLG Laboratory Working Party meeting, chaired by A/Prof Jake Shortt and Dr Colm Keane. Thank you to our guest speakers for our COVID-19 evening session last night for their stellar presentations: Prof Allen Cheng on epidemio...logy of COVID-19 in ANZ, Dr Azhar Munas on the experience with COVID-19 in Queensland, and Dr Colin McArthur on his leadership in the REMAP-CAP clinical trial. The session was hosted by ALLG Chair A/Prof Peter Mollee and chaired by A/Prof Zoe McQuilten and Dr Robert Weinkove. #ALLGtrials #virtualconferences #laboratoryscience #COVID19

12.01.2022 The ALLG is proud to support #BloodCancerAwarenessMonth! We are working collaboratively to develop Better Treatments and Better Lives for those living with blood cancers. Stay tuned to @ALLGtrials social channels for more activities and launches this September to support the blood cancer community across Australia and New Zealand.

12.01.2022 We want to take a moment to say a huge THANK YOU to everyone who made a donation in support of blood cancer research during our recent EOFY appeal. Medical research and clinical trials are vital to improving the treatment, care and quality of life for patients with blood cancer, and your donations help us to continue this life-changing work. This past year, your support helped over 480 patients suffering from leukaemia, lymphoma, myeloma and other blood disorders gain access ...to therapies and treatments not yet available for clinical practice. Thank you for your support!

12.01.2022 The ALLG welcomes the announcement from the Federal Government that acalabrutinib (Calquence) is now listed on the PBS as a second-line treatment for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). The selective BTK inhibitor was shown in the ASCEND clinical trial to have led to significant reductions in risk of death or disease progression when compared with standard treatments. This PBS listing is expected to enable approximately 1600 CLL and SLL p...atients to gain subsidised access to acalabruitinib. It is great news for CLL and SLL patients and demonstrates the impact of clinical trials in helping more patients access critical therapies and treatments. Dr Mary Ann Anderson, haematologist from the Peter MacCallum Cancer Centre and Co-Chair of the ALLG's CLL Working Party, said of the approval, "Relapsed and refractory CLL has traditionally been a difficult disease to treat, and it is wonderful to see another effective option available for Australian patients." https://www.health.gov.au//new-hope-for-australian-leukaem

11.01.2022 Check out Cancer Council Australia's Facebook Live session this afternoon (Fri, May 29) at 4pm AEST, featuring Kate Aubusson from the Sydney Morning Herald and Prof Sanchia Aranda AM discussing what easing COVID-19 restrictions will mean for people with cancer.

11.01.2022 October Scientific Meeting - Post Event Survey We would love to hear our members' thoughts and value your input. Please take a few minutes to provide us with your feedback and share any general views or comments. To be completed by Tuesday 3rd November https://surveymonkey.com/r/PJH8296

11.01.2022 Weve got 100! The Australasian Leukaemia & Lymphoma Group - ALLG HD10 clinical trial has reached the significant milestone of recruiting 100 patients to this important international cooperative trial, which aims to identify first-line treatments for Hodgkin lymphoma, or Hodgkin disease (HD), that prevent toxic side effects but maintain the effect in eliminating the cancer cells. Professor Mark Hertzberg, haematologist from the Prince of Wales Hospital (NSW) and long-time ALL...G leader, is the Principal Investigator of the Australian and New Zealand arm of this international trial established by the German Hodgkin Study Group (GHSG HD21). The trial is open at 16 sites across ANZ, including in every state and capital city in Australia, as well as several large regional centres across NSW, Queensland and Victoria. Importantly, the ALLG is expanding more trials to New Zealand, and Auckland Hospital is New Zealands site for the HD10 trial. The ALLGs international cooperative trials are important to enable access for our advanced-stage Hodgkin lymphoma patients to the most advanced treatments in the world today. The ALLG HD10 trial offers these people opportunities to access a novel therapy as part of a new regimen designed to maintain the effectiveness of treatment while potentially minimising both the short-and long-term toxicities of the standard intensive BEACOPP chemotherapy regimen. Moreover, the great majority of patients will complete all their planned therapy within a relatively brief 12-week period altogether. We hope that in future it will enable the ALLG to undertake further studies in collaboration with not only the German Hodgkin Study Group, but also with other cooperative groups in Germany and Europe more generally since we have shown how this can be undertaken successfully, Professor Hertzberg commented. The ALLG HD10 / GHSG HD21 randomised cohort is expected to close to recruitment later this year. Thanks to the Leukaemia Foundation of Australia for their support of the ALLG HD10 trial.

11.01.2022 Great news! ALLG member Associate Professor Steven Lane, haematologist from Royal Brisbane and Womens Hospital and head of the Cancer Program at QIMR Berghofer Medical Research Institute, has led the delivery of new research findings on how early genetic changes in blood and bone marrow cells can lead to the development of blood cancer. Published in the international journal Nature Communications this week, the study by A/Prof Lane and his team identified a new transcription... factor (Cdx2) involved in the development of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) in mouse cells. Additionally, they demonstrated the Cdx2 gene in pre-curser and leukaemic cells responded to the anti-leukaemic therapy azacitadine, pointing to Cdx2 gene as a potential new target for the treatment of MDS and AML. This research will help understand the way that blood cancers develop from normal cells, and whether there is an optimal way to schedule treatment to get the best outcomes for our patients, A/Prof Lane said of the study. You can access the full publication in Nature Communications (Vu, T et al. Haematopoeitic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukaemia. 2020; 11(1):3021).

10.01.2022 All of the team here at the ALLG would like to show our support for Blood Cancer Awareness Month and thank our friends at the Leukaemia Foundation for their incredible efforts towards curing and conquering every type of blood cancer #breakingbarriers #bloodcancer #bloodcancerawarenessmonth. #leukaemiafoundation

10.01.2022 Warmest congratulations to Prof Joy Ho AM and Prof Andrew Roberts AM, long-time ALLG leaders who were both yesterday appointed Members of the Order of Australia in the Queens Birthday Honours. This is a massive accolade and important recognition of their dedication to helping blood cancer patients. We appreciate and honour their decades of service to and support of ALLG clinical trials. Prof Ho has been a strong contributor to the ALLG as a member, office bearer and leader i...n clinical research since 1999, serving on the ALLG Executive Committee / Scientific Advisory Committee between 2005 and 2012 and Chair of the Laboratory Science Committee from 2005 to 2011. She was the first female President of the Haematology Society of Australia and New Zealand (HSANZ), where she served between 2013 and 2015. A 20-year member of the ALLG and Director with the ALLG Board since 2010, Prof Roberts has led the development of new treatments for leukaemia, lymphoma and myeloma through translational and clinical research. He has been an academic leader in the clinical development of the novel targeted anti-cancer drug, venetoclax, from the research laboratory through clinical trials to US FDA & TGA approval for use in treatment of selected leukaemia patients. Read more about Prof Ho and Prof Roberts on www.allg.org.au. Photos: Prof Joy Ho AM presenting the Presidential Lecture at BLOOD2019 in Perth, November 2019. Prof Andrew Roberts AM.

10.01.2022 Congratulations to A/Prof Steven Lane of QIMR from all of us at the ALLG on winning the 2020 Metcalf Prize for your stem cell research #MetcalfPrize

09.01.2022 Congratulations to ALLG members Prof Andrew Wei and Dr Natasha Anstee for being selected by the ASH Program Committee for an oral ASH presentation for the AMLM16 trial. Also a big congratulations to Prof Hang Quach and the AMN for the MM18 trial abstract acceptance at the 62nd ASH Annual Meeting and Exposition. Visit the ASH meeting website: https://www.hematology.org/meetings/annual-meeting American Society of Hematology

09.01.2022 The latest Australasian Leukaemia & Lymphoma Group - ALLG Research Report is launching at the ALLG Virtual Scientific Meeting, which starts TOMORROW morning at 8am!!!. The ALLG Research Report captures all the great work by the ALLG Members from the past year. If you are an ALLG Member and have not yet registered, please hurry and contact the ALLG for more details.

09.01.2022 This year, 16,000 Australians will be diagnosed with a blood cancer, such as leukaemia, lymphoma or myeloma. People just like Maria. Maria was diagnosed with Acute Lymphoblastic Leukaemia (ALL) in 2019. Her haematologist, Dr David Yeung, is an Australasian Leukaemia & Lymphoma Group - ALLG member and helped Maria find an ALLG clinical trial to provide the best possible treatment.... Please help the ALLG give more patients like Maria access to the best possible treatments by making a tax-deductible donation into blood cancer research today. www.allg.org.au/support-us/make-a-donation

09.01.2022 This Saturday 6th September, our friends at Myeloma Australia (@MyelomaAust_MFA) are holding their 3rd biennial National Myeloma Workshop. This interactive, virtual event brings together researchers from basic science, translational and clinical medicine and nursing to explore new ideas in the treatment of multiple myeloma. The workshop aims to promote collaboration, development of novel translational research and clinical trials across Australia and New Zealand. Key discuss...ion tops this year include Genetics and Genomics, Myeloma and Immunotherapy, and a glimpse at the future of Myeloma treatments. The ALLG is proud to support Myeloma Australia and has a virtual booth at this years Workshop. We wish all the attendees, including our ALLG Myeloma Working Party members, a productive and successful 2020 Workshop! https://myeloma.org.au//3rd-National-Myeloma-Workshop-Prog #BloodCancerAwarenessMonth

08.01.2022 What an excellent turn out of over 50 members for the brand-new session Classical Haematology, led by Prof Jeff Szer. With outstanding presentations by Dr Robert Bird, Dr Sant-Rayn Pasricha & Dr Lucy Fox

08.01.2022 May is #NationalMyelomaMonth and we want to give a big shout out to our friends at Myeloma Australia, who have been working hard this (and every!) month to raise the profile and create a community for people living with myeloma through webinars and virtual events like the Victorian State Cuppa & Catch Up yesterday. The ALLG has supported over 1,200 myeloma patients participating in clinical trials and helped deliver the benefits of new therapies. We have 3 myeloma trials currently recruiting, and another 5 new trials expected to open over the next year. Together with Myeloma Australia, we are committed to providing better treatments, better lives for those with myeloma. https://myeloma.org.au/

08.01.2022 In support of our friends and foundation partners @SnowdomeAU, the ALLG team wore RED today to highlight #itcouldbeme. This Snowdome campaign urges everyone to be aware that blood cancer can affect anyone, at any age. Every day and every month we are working hard to develop Better Treatments and Better Lives for those living with blood cancers across Australia and New Zealand. #BloodCancerAwarenessMonth.

06.01.2022 Today the team at the Australasian Leukaemia & Lymphoma Group - ALLG marks #WorldBloodCancerDay. What better way thank all of our volunteer members and clinical trial participants to commemorate this important day than to officially launch our ALLG Research Report. We are passionate about providing clinical trials which deliver better treatments and better lives for those living with blood cancer. https://www.allg.org.au//m0036c-allg-research-report-2019_

06.01.2022 Congratulations and welcome to Tanya Buchanan on her appointment as the new CEO of Cancer Council Australia. We look forward to working with you into the future @CancerCouncilOz Cancer Council Victoria

05.01.2022 It's Super Saturday at the Australasian Leukaemia & Lymphoma Group (ALLG) Virtual Scientific Meeting! ON NOW are the CML/MPN and Myeloma sessions. More to come later with CLL/Lymphoma and Acute Leukaemia/MDS Working Party sessions to go at 11am AEST and 2pm AEST, respectively.

05.01.2022 It's a Wrap!!!! Australasian Leukaemia & Lymphoma Group - ALLG thanks all the Members, Sponsors and Supporters for making the first-ever ALLG Virtual Scientific Meeting a success! We had 406 Members join us through the 6-day event and 127 Sponsor delegates, which is a record across 40 consecutive ALLG meetings. Our coming together as a blood cancer community in challenging times - even in a virtual setting - is incredibly important. We must continue our leadership in clinical trials to help blood cancer patients, and your support is truly appreciated.

03.01.2022 The European Hematology Association (EHA) 25th Annual Congress kicks off tonight with its new virtual platform. The Australasian Leukaemia & Lymphoma Group - ALLG has a virtual exhibition booth at EHA this year, and we are excited to support ALLG members and engage with our many international collaborators. Stay tuned for ALLG updates from #EHA25Virtual.

03.01.2022 The American Society of Hematology annual congress is going fully virtual in December. The abstract deadline has been extended to August 10. The ALLG is excited to "see" you @ASH to accelerate blood cancer clinical trials! https://www.hematology.org/meetings/annual-meeting/abstracts

03.01.2022 Cancer Council Victoria has released a Telehealth Fact Sheet to help people living with cancer and their carers navigate the challenges of having medical appointments by phone or video. You can download the telehealth tips here: https://www.cancervic.org.au//Telehealth-patient-fact-shee

03.01.2022 In a significant advancement for patients living with systemic light-chain (AL) amyloidosis, the main publication for the ALLG MM13 clinical trial has been published in the Journal of Clinical Oncology. The results of the trial are unprecedented in AL amyloidosis. The trial showed that bortezomib significantly improved response rates and overall survival, with the absolute improvement in survival of approximately 30% with the addition of bortezomib a staggering result almo...st never seen in blood disorders. Led by ALLG Scientific Advisory Committee Chair, Associate Professor Peter Mollee, this trial was an important international collaboration with the European Myeloma Network (EMN), bringing new therapies to Australian patients with AL amyloidosis, particularly new combinations of therapies. We thank the Leukaemia Foundation of Australia for their support of this important trial. Read more in the latest issue of ALLG News here: https://www.allg.org.au///allg-news-aug-2020-final_web.pdf

02.01.2022 Remembrance Day 2020. On the 11th hour of the 11th day of the 11th month we shall remember them #LestWeForget #WeRememberThem

02.01.2022 Blood cancer patients rely on you donating blood and plasma. It's an area of critical need in ANZ, so our patients need your help urgently. Support the Australasian Leukaemia & Lymphoma Group (ALLG) by donating blood today. #NationalBloodDonorWeek ... @lifebloodau https://www.donateblood.com.au/national-blood-donor-week-20

02.01.2022 Our friends @LymphomaAustralia are hosting an upcoming chronic lymphocytic leukaemia (CLL)-focused online education event featuring Associate Professor Matthew Davids from Harvard Medical School and the Dana Farber Cancer Institute in the US. A/Prof Davids will join a panel of patient and clinical experts including Dr Jason Butler, Dr Brian Koffman and Deborah Sims. The ALLG is a proud supporter of this event. Event: CLL Education Day Webinar... Date: 18 August 2020 Time: from 9am AEST Learn more and register via http://www.lymphoma.org.au/page/1276/cll-education-day

01.01.2022 Thank you to Clinical Oncology Society of Australia - COSA and Icon Group for delivering a fantastic pre-conference Tele-trials workshop last week. The ALLG’s CEO, Delaine Smith spoke on the topic of implementation of tele-trials and the experience of a cooperative trial group sponsor #teletrials